Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
We report a case of a seven-yr-old girl with a PAH treated with continuation therapy of bosentan and sildenafil. The combination therapy revealed safety and efficacy in long-term follow up.
Brancaccio
Gianluca
G
Department of Pediatric Cardiology and Cardiac Surgery, Ospedale Pediatrico Bambino Gesù, Rome, Italy. gbrancaccio70@hotmail.com
Toscano
Alessandra
A
Bevilacqua
Maurizio
M
Di Chiara
Luca
L
Parisi
Francesco
F
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D002648:Child; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007262:Infusions, Intravenous; D016040:Lung Transplantation / Q000502:physiology*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000627:therapeutic use*; D013450:Sulfones / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D010879:Piperazines; D011687:Purines; D013449:Sulfonamides; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D011464:Epoprostenol; D000077300:Bosentan